Pinnacle Wealth Management Advisory Group LLC trimmed its position in Bristol-Myers Squibb Co (NYSE:BMY) by 3.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,293 shares of the biopharmaceutical company’s stock after selling 588 shares during the period. Pinnacle Wealth Management Advisory Group LLC’s holdings in Bristol-Myers Squibb were worth $1,003,000 at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in the stock. Roosevelt Investment Group Inc. acquired a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $1,141,000. ST Germain D J Co. Inc. raised its position in shares of Bristol-Myers Squibb by 33.6% in the 4th quarter. ST Germain D J Co. Inc. now owns 8,663 shares of the biopharmaceutical company’s stock valued at $450,000 after acquiring an additional 2,180 shares during the period. Meridian Wealth Management LLC raised its position in shares of Bristol-Myers Squibb by 75.5% in the 4th quarter. Meridian Wealth Management LLC now owns 21,720 shares of the biopharmaceutical company’s stock valued at $1,129,000 after acquiring an additional 9,341 shares during the period. LSV Asset Management raised its position in shares of Bristol-Myers Squibb by 354.1% in the 4th quarter. LSV Asset Management now owns 168,600 shares of the biopharmaceutical company’s stock valued at $8,763,000 after acquiring an additional 131,469 shares during the period. Finally, Capital Investment Counsel Inc raised its position in shares of Bristol-Myers Squibb by 3.4% in the 4th quarter. Capital Investment Counsel Inc now owns 6,156 shares of the biopharmaceutical company’s stock valued at $320,000 after acquiring an additional 200 shares during the period. Institutional investors and hedge funds own 72.56% of the company’s stock.
BMY has been the topic of a number of analyst reports. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, January 16th. Credit Suisse Group restated a “hold” rating and set a $59.00 target price on shares of Bristol-Myers Squibb in a report on Thursday, December 13th. ValuEngine downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Friday, January 4th. Bank of America set a $53.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Friday, January 25th. Finally, BMO Capital Markets upgraded shares of Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and set a $60.00 target price on the stock in a report on Thursday, December 6th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $59.40.
Shares of BMY opened at $50.97 on Thursday. The company has a market cap of $82.25 billion, a PE ratio of 12.81, a price-to-earnings-growth ratio of 2.25 and a beta of 0.83. Bristol-Myers Squibb Co has a twelve month low of $44.30 and a twelve month high of $67.44. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.53 and a quick ratio of 1.40.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.09. The company had revenue of $5.97 billion during the quarter, compared to analysts’ expectations of $5.95 billion. Bristol-Myers Squibb had a net margin of 21.95% and a return on equity of 50.03%. The business’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period last year, the business earned $0.68 EPS. As a group, sell-side analysts expect that Bristol-Myers Squibb Co will post 4.15 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be paid a dividend of $0.41 per share. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $1.64 annualized dividend and a dividend yield of 3.22%. Bristol-Myers Squibb’s dividend payout ratio is currently 41.21%.
COPYRIGHT VIOLATION WARNING: “Bristol-Myers Squibb Co (BMY) Shares Sold by Pinnacle Wealth Management Advisory Group LLC” was originally reported by Fairfield Current and is the sole property of of Fairfield Current. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.fairfieldcurrent.com/news/2019/03/14/pinnacle-wealth-management-advisory-group-llc-sells-588-shares-of-bristol-myers-squibb-co-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Story: What are the benefits of a balanced fund?
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.